DONGKOOK PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16,990 KRW | +2.60% |
|
+4.36% | +5.14% |
| Sales 2024 * | 810B 595M 49.62B | Sales 2025 * | 894B 656M 54.72B | Capitalization | 747B 548M 45.73B |
|---|---|---|---|---|---|
| Net income 2024 * | 55B 40.37M 3.37B | Net income 2025 * | 73B 53.58M 4.47B | EV / Sales 2024 * | 0.79 x |
| Net cash position 2024 * | 103B 75.38M 6.29B | Net cash position 2025 * | 90.45B 66.39M 5.54B | EV / Sales 2025 * | 0.73 x |
| P/E ratio 2024 * |
13.7
x | P/E ratio 2025 * |
10.4
x | Employees | 1,105 |
| Yield 2024 * |
1.06% | Yield 2025 * |
1.06% | Free-Float | 53.83% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.60% | ||
| 1 week | +4.36% | ||
| Current month | +3.09% | ||
| 1 month | +2.23% | ||
| 3 months | -2.52% | ||
| 6 months | +5.20% | ||
| Current year | +5.14% |
1 week
16 280.00
16 990.00
1 month
15 700.0016 990.00
Current year
14 990.0019 620.00
1 year
13 000.0019 620.00
3 years
13 000.0029 500.00
5 years
10 720.0036 150.00
10 years
4 900.0036 150.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joon-Ho Song
CEO | Chief Executive Officer | 56 | 01/12/01 |
Gi-Beum Kwon
CHM | Chairman | 57 | 01/94/01 |
Yoon-Hwan Son
AUD | Comptroller/Controller/Auditor | 65 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gi-Beum Kwon
CHM | Chairman | 57 | 01/94/01 |
Joon-Ho Song
CEO | Chief Executive Officer | 56 | 01/12/01 |
Chae-Gun Im
BRD | Director/Board Member | 55 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +2.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 16,990 | +2.60% | 138,656 |
| 02/24/02 | 16,560 | +0.49% | 99,275 |
| 30/24/30 | 16,480 | -0.72% | 97,131 |
| 29/24/29 | 16,600 | +1.97% | 127,196 |
| 26/24/26 | 16,280 | +2.13% | 99,569 |
End-of-day quote Korea S.E., May 03, 2024
More quotes
DongKook Pharmaceutical Co., Ltd. is a Korea-based company engaged in the development, manufacture and distribution of pharmaceuticals. The Company develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. It also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The Company distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
16,990
KRW
Average target price
24,000
KRW
Spread / Average Target
+41.26%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.14% | 551M | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- A086450 Stock
